Screener
Ultragenyx Pharmaceutical RARE Proceeds From Issuance Of Common Stock At Market Offering
Proceeds From Issuance Of Common Stock At Market Offering at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept rare:ProceedsFromIssuanceOfCommonStockAtMarketOffering.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
FAQ
- What is Ultragenyx Pharmaceutical's proceeds from issuance of common stock at market offering?
- Ultragenyx Pharmaceutical (RARE) reported proceeds from issuance of common stock at market offering of $272K in Q4 2025.
- What does proceeds from issuance of common stock at market offering mean?
- This represents cash inflows generated from selling common stock directly into the open market, often through 'at-the-market' (ATM) programs. Unlike large underwritten offerings, these are typically smaller, incremental sales used to manage liquidity needs. Investors monitor this to gauge the company's ongoing reliance on equity markets for operational funding.
Ask your AI about Ultragenyx Pharmaceutical's proceeds from issuance of common stock at market offering.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude